Ari M. Melnick, MD, on Activated B-Cell–Like DLBCL: Gain-of-Function Mutations and Resistance to Ibrutinib
Ari M. Melnick, MD, of Weill Cornell Medicine, discusses the BCL10 mutation in patients with activated B-cell–like diffuse large B-cell lymphoma, and his study results which showed that the mutation should be considered as a biomarker for ibrutinib resistance so that alternative targeted treatments can be prioritized (Abstract 3).